Centogene, Twist Join Forces For Custom Test Kits For Rare Diseases

by Vandana Singh, Benzinga Editor

October 6, 2021 3:49 PM | 1 min read | Make a Comment

Centogene NV CNTG and Twist Bioscience Corporation TWST have signed a contract to develop and commercialize custom assay kits for rare diseases.
The financial details of the deal were not disclosed.
Related: Twist Bioscience, Boehringer Ingelheim Joins Forces For Antibody Research Programs.
The product offering will combine Centogene's Bio/Databank with Twist Bioscience's library preparation and target enrichment capabilities to deliver multiple rare disease diagnosis and analysis assays.
Price Action: CNTG stock is up 0.39% at $10.30, while TWST stock is down 2.68% at $96.69 during the market session on the last check Wednesday.